Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC

NEXT STORY
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
PREV STORY
Immunoassay Market Worth $46.5 Billion by 2028, Growing at a CAGR of 7.5% From 2021- Exclusive Report by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Telix Group Expands Prostate Imaging Capability through ININ Technology Partnership

MELBOURNE, Australia and LIEGE, Belgium, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Advanced Nuclear Medicine ...

author_avatar
NASDAQ Market News

TESARO Announces Presentation of Niraparib Data at the 2016 IGCS Biennial Meeting

WALTHAM, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

author_avatar
NASDAQ Market News

Amicus Therapeutics to Highlight Fabry Disease Program at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)

CRANBURY, N.J., Aug. 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that ...

author_avatar
NASDAQ Market News